Asthma Treatment Update: Benralizumab's Impact on Corticosteroid Use
How the SHAMAL Trial Offers New Hope for Severe Eosinophilic Asthma Patients
Topline:
A groundbreaking SHAMAL phase IV trial reveals that Benralizumab (Fasenra) enables severe eosinophilic asthma patients to safely reduce high-dose inhaled corticosteroids without compromising asthma control, offering new insights for healthcare providers and patients alike.
Study Details:
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.